Glaxo pays $1B to up its stake in India; Janssen shells out to settle Montana Risperdal suit;

@FiercePharma: Top-read this weekend: Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year. Story | Follow @FiercePharma

@TracyStaton: RT from BioPharmaJosh: WSJ looks at how Johnson & Johnson beat out Novartis & Celgene for Imbruvica. Story via the Wall Street Journal (sub. req.) | Follow @TracyStaton

@EricPFierce: EMA wants warning on Ambien type drugs that landed Kerry Kennedy in court. More | Follow @EricPFierce

@CarlyHFierce: AstraZeneca says Nexium pills with Ranbaxy ingredient are safe to use. Article | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) is paying £625 million ($1.03 billion) to raise its stake in its Indian subsidiary by 75%. News (sub. req.)

> The Association of the British Pharmaceutical Industry (ABPI) has again voiced concern that patients in some parts of England are not getting access to drugs that have been approved by NICE, the National Health Service's cost watchdog. More

> Johnson & Johnson's ($JNJ) Janssen unit has settled a Risperdal marketing lawsuit with the state of Montana for $5.9 million. Report

> Larger rivals are exploring a bid for Orphan drugmaker InterMune ($ITMN), Reuters reports. More

> Takeda has filed a New Drug Application in Japan for diabetes drug trelagliptin succinate. News (sub. req.)

> An item in the U.S. budget seeking to exclude tax inversions may hit Valeant Pharmaceuticals ($VRX) hard; the company moved its headquarters from the U.S. to Canada, seeking tax benefits, after a $3.3. billion reverse merge with Biovail in 2010. Report

> Teva ($TEVA) has launched generic tablets of Genentech's cancer drug Xeloda in the U.S. Release

> Reckitt Benckiser has acquired the global rights to intimate lubricants brand K-Y from Johnson & Johnson's ($JNJ) McNeil subsidiary. Release

Medical Device News

@FierceMedDev: Score for Georgetown U.--a team there developed a Dx that appears to predict the onset of Alzheimer's. Story | Follow @FierceMedDev

@MarkHFierce: Here are 10 M&A med tech deals announced or closed in 2013 set to have a real impact on the industry. Special Report | Follow @MarkHFierce

@MichaelGFierce: Boston Heart launches a new inflammation test for cardiovascular disease. More from FierceDiagnostics | Follow @MichaelGFierce

@EmilyWFierce: Not just for humans anymore: new medical devices for dogs measure everything from anxiety to activity level. Article | Follow @EmilyWFierce

> Surgical tool maker Invuity will boost its sales force and move to a larger HQ. More

> Olympus is selling the OP-1 plant it bought from Stryker 4 years ago. Story

> Smith & Nephew and OrthoSensor to co-market orthopedic surgical tech and tools. Item

Biotech News

@FierceBiotech: J&J partners with a biotech startup on a new approach to Alzheimer's. More | Follow @FierceBiotech

@JohnCFierce: I've seen plenty of instances of chutzpah in biotech, but these Northwest Bio claims cross a line into BS terrain. News | Follow @JohnCFierce

@DamianFierce: J&J, Pharmacyclics and the future of Big Pharma dealmaking. Story | Follow @DamianFierce

@EmilyMFierce: NIH faces flat funds under president's 2015 budget proposal . More | Follow @EmilyMFierce

> Regeneron, Sanofi and Amgen shares suffer on FDA's frets about PCSK9 class. Article

> Regado shares pop as drug wins fast-track status. Item

Biotech IT News

> Illumina backs Venter's plan to create world's largest human genome sequencing center. Story

> Big Data, social media and mobile double their share of biopharma marketing mix. Report

> Google-backed genomics alliance details data interoperability plans. Story

> FDA informatics chief: NGS is an immediate priority for the agency. Article

> Scripps shares genetic sequences of healthy elderly to boost Alzheimer's and cancer research. Article

> Eli Lilly begins sharing photos on Instagram. Brief

CRO News

> WuXi soars on manufacturing and plots another leap in 2014. Story

> INC buys its way into the Middle East with MEK deal. Article

> Celerion stretches into South Korea for translational studies. Story

> Harlan partners up for early-stage drug development. News

> Columbia Labs inches forward in its first quarter as a CRO. Story

> Quintiles' bankrollers eye another $1B in second offering. Brief

And Finally... Increasingly inexpensive components created for the smartphone business are helping spur a market for wearable pet activity trackers. They keep tabs on dogs' fitness the same way the human versions do, monitoring stats like heart and respiratory rates. More (sub. req.)

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.